Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
OSUR 
OraSure Technologies Inc (OSUR)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
03/27/2025: OSUR (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Moderate Performance
These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.
Analysis of Past Performance
Type Stock | Historic Profit -41.73% | Avg. Invested days 32 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 03/27/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 261.05M USD | Price to earnings Ratio - | 1Y Target Price 5 |
Price to earnings Ratio - | 1Y Target Price 5 | ||
Volume (30-day avg) 921735 | Beta -0.02 | 52 Weeks Range 2.69 - 6.35 | Updated Date 03/27/2025 |
52 Weeks Range 2.69 - 6.35 | Updated Date 03/27/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.27 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2025-02-25 | When After Market | Estimate -0.0107 | Actual -0.06 |
Profitability
Profit Margin -10.49% | Operating Margin (TTM) -29.95% |
Management Effectiveness
Return on Assets (TTM) -2.68% | Return on Equity (TTM) -4.64% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 7893457 | Price to Sales(TTM) 1.4 |
Enterprise Value 7893457 | Price to Sales(TTM) 1.4 | ||
Enterprise Value to Revenue 0.04 | Enterprise Value to EBITDA 2.22 | Shares Outstanding 74800096 | Shares Floating 67336574 |
Shares Outstanding 74800096 | Shares Floating 67336574 | ||
Percent Insiders 4.07 | Percent Institutions 91.51 |
Analyst Ratings
Rating 3.4 | Target Price 5.75 | Buy - | Strong Buy 1 |
Buy - | Strong Buy 1 | ||
Hold 4 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
OraSure Technologies Inc
Company Overview
History and Background
OraSure Technologies Inc. was founded in 1988. Initially focused on oral fluid collection devices, it expanded into diagnostics, particularly infectious disease testing. A key milestone was the FDA approval of its OraQuick HIV test, enabling rapid, point-of-care testing.
Core Business Areas
- Molecular Solutions: Develops and manufactures molecular collection devices for various applications, including infectious disease testing, genetic testing, and microbiome analysis. Includes products like ORAcollect Dx and ORAcollect RNA.
- In Vitro Diagnostic Tests: Focuses on developing, manufacturing, and marketing rapid, point-of-care diagnostic tests for infectious diseases, including HIV and hepatitis C. Includes products like OraQuick HIV self-test.
- International Diagnostics: Sales of diagnostic tests and collection devices outside of the US.
Leadership and Structure
The leadership team includes Lisa M. Nibauer (President & CEO). The company has a typical corporate structure with departments such as R&D, Sales, Marketing, Finance, and Operations.
Top Products and Market Share
Key Offerings
- OraQuick HIV Self-Test: A rapid, point-of-care HIV test for home use. Market share information is difficult to obtain precisely but OraSure is a significant player. Competitors include lab-based HIV testing, and other POC rapid tests.
- ORAcollect Dx: An oral fluid collection device used for diagnostic testing. Market share information is not publicly available. Competitors include other saliva collection methods or swabs provided by diagnostic assay manufacturers.
- ORAcollect RNA: A collection kit to stabilizes RNA from saliva samples. The amount of revenue is unkown. Competitors include Puritan Medical Products and DNA Genotek.
Market Dynamics
Industry Overview
The diagnostics industry is experiencing growth driven by increasing demand for point-of-care testing, advancements in molecular diagnostics, and growing awareness of infectious diseases. The demand for diagnostic products fluctuates with market conditions and disease prevalence (e.g. COVID-19).
Positioning
OraSure is positioned as a provider of rapid, point-of-care diagnostic tests and oral fluid collection devices. Its competitive advantages include its established brand recognition, proprietary technologies, and distribution network.
Total Addressable Market (TAM)
The global diagnostics market is estimated to be in the hundreds of billions of dollars. OraSure focuses on niche segments within this market, such as infectious disease testing and oral fluid collection. OraSure's positioning allows it to capture a portion of this TAM through its specialized product offerings.
Upturn SWOT Analysis
Strengths
- Established Brand Recognition
- Proprietary Technologies
- Strong Distribution Network
- Focus on Point-of-Care Testing
- FDA-Approved Products
Weaknesses
- Dependence on a Limited Number of Products
- Susceptibility to Regulatory Changes
- Competition from Larger Diagnostics Companies
- Fluctuating sales related to public health crisis.
Opportunities
- Expansion into New Geographic Markets
- Development of New Diagnostic Tests
- Partnerships with Healthcare Providers
- Increasing Demand for Point-of-Care Testing
- Expanding molecular solutions for genetic testing.
Threats
- Increased Competition
- Changes in Reimbursement Policies
- Technological Advancements by Competitors
- Economic Downturns
- Unfavorable FDA decisions
Competitors and Market Share
Key Competitors
- Abbott (ABT)
- Roche Holding AG (RHHBY)
- Thermo Fisher Scientific (TMO)
Competitive Landscape
OraSure faces competition from larger, more established diagnostics companies with greater resources and broader product portfolios. OraSure's advantages include its focus on point-of-care testing and its established brand recognition in certain niche markets.
Major Acquisitions
CoreBiome, Inc.
- Year: 2020
- Acquisition Price (USD millions): 15.8
- Strategic Rationale: Expanded OraSure's portfolio of microbiome collection and analysis solutions.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been variable, with spikes during periods of heightened demand for its products, such as during public health emergencies, followed by slower growth as demand normalizes.
Future Projections: Future growth is projected to be in line with growth of molecular solutions business as well as sales of diagnostic tests. Analyst estimates will provide projections.
Recent Initiatives: Recent initiatives include expanding product lines for molecular collection and diagnostics tests, and expanding partnerships to enhance distribution.
Summary
OraSure Technologies is a niche player in the diagnostics market with strengths in point-of-care testing and oral fluid collection. The company's growth is dependent on successfully commercializing new products and expanding into new markets. It needs to monitor competition and regulatory changes, as well as ensure that its supply chain can meet the market demand for their products.
Similar Companies
- ABT
- RHHBY
- TMO
- DGX
- LH
Sources and Disclaimers
Data Sources:
- Company SEC Filings (10-K, 10-Q)
- Company Website
- Industry Reports
- Analyst Reports
Disclaimers:
The information provided is for informational purposes only and should not be construed as financial advice. Investment decisions should be based on thorough research and consultation with a qualified financial advisor. Market share estimates are approximate and may vary based on the source.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About OraSure Technologies Inc
Exchange NASDAQ | Headquaters Bethlehem, PA, United States | ||
IPO Launch date 1986-11-12 | President, CEO & Director Ms. Carrie Eglinton Manner | ||
Sector Healthcare | Industry Medical Instruments & Supplies | Full time employees 501 | Website https://www.orasure.com |
Full time employees 501 | Website https://www.orasure.com | ||
OraSure Technologies, Inc., together with its subsidiaries, develops, manufactures, markets, sells, and distributes diagnostic products, specimen collection devices, and other diagnostic products in the United States, Europe, Africa, and internationally. The company's products include OraQuick Rapid HIV test, OraQuick In-Home HIV test, OraQuick HIV self-test, OraQuick HCV rapid antibody test and self-test, Syphilis health check rapid diagnostic test, OraQuick Ebola rapid antigen test, InteliSwab COVID-19 rapid test, InteliSwab COVID-19 rapid test pro, InteliSwab COVID-19 rapid test rx, and OraSure oral fluid collection device used in conjunction with screening and confirmatory tests for HIV-1 antibodies; Intercept drug testing systems; immunoassay tests and reagents; and Q.E.D. saliva alcohol test. It also offers genomic products under the Oragene and ORAcollect brands for collecting genetic material from human saliva; and Colli-Pee collection devices for the volumetric collection of void urine samples. In addition, the company provides microbiome products, such as OMNIgene GUT for self-collecting microbial DNA from feces or stool samples for gut microbiome profiling; OMNIgene GUT DNA and RNA collection devices; OMNIgene SALIVA DNA and RNA collection devices; and OMNIgene GUT Dx collection device for collection of human fecal samples and the stabilization of DNA from the bacterial community. Further, it offers other diagnostic products, such as immunoassays and other in vitro diagnostic tests. Additionally, the company develops a molecular self-test for chlamydia trachomatis and neisseria gonorrhoeae. The company markets its products to clinical laboratories, hospitals, clinics, community-based organizations and other public health organizations, distributors, government agencies, physicians' offices, commercial and industrial entities, disease risk management, diagnostics, pharmaceutical, biotech, nutrition, companion animal, and environmental markets. OraSure Technologies, Inc. was incorporated in 2000 and is h
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.